Skip to main content
logo
Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
3.060
-0.270 (-8.11%)
At close: Oct 30, 2026, 4:00 PM EDT
3.050
-0.010 (-0.33%)
After-hours: Oct 30, 2026, 5:07 PM EDT

Immutep Revenue

In the fiscal year ending June 30, 2026, Immutep had annual revenue of 14.60M AUD with 24,344.44% growth. Immutep had revenue of 10.50M in the half year ending June 30, 2026, with 34,682.21% growth.

Revenue (ttm)
14.60M AUD
Revenue Growth
+24,344.44%
P/S Ratio
1.73
Revenue / Employee
470,824 AUD
Employees
31
Market Cap
23.85M USD

Revenue Chart

Chart
* This company reports financials in AUD.

Revenue by Segment

Chart
  • Immunotherapy 5.03M 99.8%
  • Unallocated 9.24K 0.2%
Fiscal year ended Jun 30, 2025 See the full Immutep breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Jun 30, 202614.60M14.54M24,344.44%
Jun 30, 202559.71K-59.38K-49.86%
Jun 30, 2024119.09K-72.63K-37.88%
Jun 30, 2023191.72K-62.67K-24.63%
Jun 30, 2022254.39K-58.45K-18.68%
Jun 30, 2021312.84K-7.45M-95.97%
Jun 30, 20207.77M6.47M499.78%
Jun 30, 20191.29M-2.34M-64.42%
Jun 30, 20183.64M2.84M354.63%
Jun 30, 2017800.46K625.41K357.27%
Jun 30, 2016175.05K--
Jun 30, 2015---
Jun 30, 2014---
Jun 30, 2013---
Jun 30, 2012---
Jun 30, 2011---
Jun 30, 2010---
Jun 30, 2009---
Jun 30, 2008---
Jun 30, 2007---
Jun 30, 2006---
Jun 30, 2005---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Karyopharm Therapeutics146.62M
BioStem Technologies34.59M
Evaxion7.49M
BeyondSpring1.88M
IGC Pharma1.11M
Revenue Rankings

IMMP News

More News